≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback

Disorder of visual pathways, unspecified

DOID Endpoint Browser PheWeb

H7_VISUALPATHNAS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — H47.7
  • Hospital discharge: ICD-9 — 3779
  • Cause of death: ICD-10 — H47.7
  • Cause of death: ICD-9 — 3779

2 out of 7 registries used, show all original rules.

64

4. Check minimum number of events

None

64

5. Include endpoints

None

64

6. Filter based on genotype QC (FinnGen only)

61

Control definitions (FinnGen only)

Control exclude
H7_OPTNERVE

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
H47
Name in latin
Morbositas partis non specificatae tractuum opticorum

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 537 259 275
Only index persons 443 214 229
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 18.91 22.93 14.70
Only index persons 24.82 34.55 15.73

-FinnGen-

Key figures

All Female Male
Number of individuals 61 33 28
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 48.12 50.88 44.87

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
64
Matched controls
640
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H47.7
ICD-10 Finland
Disorder of visual pathways, unspecified
+∞
86.5
62
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
13.2
23.4
30
40
Z3229
NOMESCO Finland
Other healthcare associate professional
8.6
15.6
27
50
H47.2
ICD-10 Finland
Optic atrophy
+∞
11.8
11
*
F79.0
ICD-10 Finland
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
35.1
11.3
14
5
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
6.4
10.9
24
55
RT274, ,
NOMESCO Finland
+∞
10.7
10
*
N05BA09
ATC
clobazam; oral
65.2
10.0
11
*
H54.7
ICD-10 Finland
Unspecified visual loss
116.5
9.7
10
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
6.5
9.5
19
39
P85
ICPC
Mental retardation
43.5
9.4
11
*
XCK00
NOMESCO Finland
Perimetry
12.1
8.9
16
17
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
+∞
8.5
8
*
181
Kela drug reimbursment
Retigabine and vigabatrin
+∞
8.5
8
*
M03BX01
ATC
baclofen; systemic
38.8
8.3
10
*
RL140, ,
NOMESCO Finland
18.6
7.5
11
7
RT190, ,
NOMESCO Finland
+∞
7.4
7
*
RS142, ,
NOMESCO Finland
+∞
7.4
7
*
G80.9
ICD-10 Finland
Cerebral palsy, unspecified
+∞
7.4
7
*
N03AG04
ATC
vigabatrin; oral
+∞
7.4
7
*
Z2446
NOMESCO Finland
Social worker
4.6
7.2
22
65
RT160, ,
NOMESCO Finland
25.7
6.9
9
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.1
6.7
26
92
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
6.6
6.6
17
33
H51.9
ICD-10 Finland
Disorder of binocular movement, unspecified
77.2
6.6
7
*
G40.4
ICD-10 Finland
Other generalized epilepsy and epileptic syndromes
77.2
6.6
7
*
RT490, ,
NOMESCO Finland
77.2
6.6
7
*
H53.4
ICD-10 Finland
Visual field defects
30.0
6.4
8
*
G80.8
ICD-10 Finland
Other cerebral palsy
+∞
6.3
6
*
F72.0
ICD-10 Finland
Severe mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
6.3
6
*
3AX01, ,
NOMESCO Finland
+∞
6.3
6
*
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
14.5
6.3
10
8
N05CD08
ATC
midazolam; nasal, systemic
14.5
6.3
10
8
R4110
NOMESCO Finland
Physiotherapy
3.6
6.1
34
152
N03AX14
ATC
levetiracetam; systemic
10.8
6.1
11
12
G40.9
ICD-10 Finland
Epilepsy, unspecified
10.8
6.1
11
12
XCD10
NOMESCO Finland
Electrophysiological examination of eye
12.9
6.0
10
9

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
21
66
4.25
6.28
1.4
1.5
—
—
—
0
0
33
167
3.02
4.50
2.8
3.9
—
—
—
0
0
46
293
3.03
3.93
12.2
9.2
1.21
1.22
mmol/l
0.46
40
256
22
95
3.01
3.89
17.1
12.7
24.55
25.10
mmol/l
0.21
22
95
6
6
10.85
3.57
4.0
3.7
—
—
—
0
0
31
170
2.60
3.41
3.0
4.1
0.77
0.30
e6/l
0.40
26
134
36
216
2.52
3.24
3.5
4.7
235.28
65.57
e6/l
0.64
29
157
18
77
2.86
3.17
10.7
8.0
—
—
—
0
0
22
105
2.67
3.16
3.9
10.6
—
—
—
0
0
10
26
4.36
3.14
2.4
1.6
—
—
—
0
0
25
128
2.56
3.12
4.2
4.2
—
—
—
0
0
48
334
2.75
3.11
8.3
6.0
6.69
6.53
mmol/l
0.18
43
316
19
85
2.76
3.08
3.8
10.6
24.16
23.39
mmol/l
0.39
19
85
19
90
2.58
2.73
12.5
13.3
—
—
—
0
0
27
154
2.30
2.59
3.9
2.9
—
—
—
0
0
31
190
2.22
2.48
3.0
4.0
140.76
368.82
e6/l
0.29
26
150
5
8
6.66
2.41
1.6
4.4
1.72
1.65
umol/l
—
5
8
5
8
6.66
2.41
5.0
4.6
—
—
—
0
0
19
96
2.39
2.36
11.3
7.2
—
7.43
—
0
7
14
62
2.61
2.27
14.3
7.7
105.14
103.11
mmol/l
0.91
14
62
8
26
3.36
2.09
12.6
15.0
—
—
—
0
0
6
15
4.30
2.09
1.3
3.4
2317.83
314.73
mg/l
—
6
15
58
494
2.85
1.98
21.7
17.4
14.41
14.86
%
0.36
58
487
5
12
4.42
1.86
1.4
3.7
3.48
3.74
mmol/l
—
5
12
25
157
1.97
1.76
2.8
2.0
360.44
234.13
u/l
0.35
25
149
14
70
2.28
1.75
1.6
1.7
—
—
—
0
0
26
166
1.95
1.75
1.6
2.2
98.72
97.06
pmol/l
0.06
14
79
5
13
4.07
1.75
5.0
3.6
—
—
—
0
0
35
248
1.91
1.72
7.1
5.9
0.00
0.00
estimate
—
6
44
35
249
1.90
1.69
6.0
3.9
0.00
0.00
estimate
—
7
47
35
250
1.88
1.66
6.1
4.0
0.00
0.00
estimate
—
5
42
10
44
2.50
1.65
18.6
14.6
1.41
1.35
mmol/l
—
10
44
7
26
2.89
1.63
26.6
15.5
21.57
23.80
mmol/l
—
7
26
8
33
2.62
1.60
4.0
4.0
—
—
—
0
0
7
27
2.78
1.56
6.0
4.2
—
—
—
0
0
45
357
1.88
1.45
5.7
4.5
—
—
—
0
0
30
211
1.79
1.44
5.5
3.7
—
5.77
—
0
20
20
124
1.89
1.43
5.9
3.8
—
—
—
0
0
6
25
2.54
1.27
3.3
3.1
—
—
—
0
0
7
132
0.47
1.15
2.4
3.3
308.29
7244.56
umol/l
—
7
109
27
194
1.68
1.15
2.1
2.5
—
—
—
0
0
38
301
1.65
1.10
4.5
8.2
0.04
0.04
e9/l
0.13
33
257
37
293
1.62
1.06
4.4
8.4
—
—
—
0
0
38
303
1.63
1.05
4.5
8.2
0.63
0.57
e9/l
0.80
33
260
59
538
2.24
1.00
24.0
16.5
3.96
3.98
mmol/l
0.17
59
526
0
30
0.00
1.00
0.0
1.8
—
—
—
0
0
6
29
2.18
0.92
2.8
5.1
30.17
26.56
nmol/l
—
6
29
6
32
1.96
0.84
1.3
1.2
—
—
—
0
0
6
33
1.90
0.81
2.5
2.1
—
—
—
0
0
0
24
0.00
0.81
0.0
2.3
—
—
—
0
0
0
25
0.00
0.81
0.0
1.5
—
—
—
0
0
0
27
0.00
0.79
0.0
1.4
—
—
—
0
0
5
23
2.27
0.78
3.8
2.2
—
—
—
0
0
57
522
1.84
0.77
19.1
14.4
35.88
22.92
mg/l
1.49
46
400
9
56
1.70
0.76
2.7
3.4
8.52
9.29
g/l
—
9
51
17
120
1.57
0.74
5.1
3.7
0.00
0.00
estimate
—
6
44
8
52
1.61
0.62
1.5
1.6
—
—
—
0
0
0
20
0.00
0.61
0.0
1.0
—
—
—
0
0
21
163
1.43
0.58
3.0
3.7
22.16
46.26
ng/l
0.95
13
111
34
294
1.33
0.48
6.3
10.6
0.00
0.00
e9/l
0.50
28
229
5
31
1.66
0.44
2.6
2.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
339.32
—
0
8
0
17
0.00
0.41
0.0
1.5
—
—
—
0
0
15
117
1.37
0.40
5.3
9.9
1.08
1.22
mmol/l
1.31
15
110
14
174
0.75
0.35
2.9
2.1
—
—
—
0
0
16
131
1.30
0.31
4.5
3.6
—
—
—
0
0
11
138
0.75
0.29
3.5
4.2
—
—
—
0
0
42
389
1.23
0.27
3.8
4.7
10.38
10.43
mm/h
0.01
37
360
9
72
1.29
0.27
2.4
2.4
370.00
372.82
nmol/l
—
9
66
6
80
0.72
0.26
2.0
1.7
—
—
—
0
0
20
174
1.22
0.23
1.6
1.7
2.36
1.98
g/l
0.46
12
95
42
446
0.83
0.22
4.9
4.2
6.19
5.85
mmol/l
0.75
42
412
5
41
1.24
0.22
1.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
3.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
5.5
—
0.82
—
0
10
0
10
0.00
0.21
0.0
51.0
—
159.90
—
0
10
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
51
1.19
0.20
1.2
1.6
—
—
—
0
0
7
86
0.79
0.15
1.4
2.0
—
—
—
0
0
5
45
1.12
0.10
1.4
1.2
—
151.02
—
0
13
19
175
1.12
0.10
3.9
8.8
—
—
—
0
0
5
46
1.09
0.10
1.2
1.4
—
—
—
0
0
6
71
0.83
0.08
1.3
1.5
—
—
—
0
0
7
81
0.85
0.07
1.3
1.4
—
—
—
0
0
7
82
0.84
0.07
1.6
2.3
1023.00
97.64
ug/g
—
7
61
7
84
0.81
0.07
2.0
2.0
—
—
—
0
0
15
140
1.09
0.05
4.2
3.0
—
—
—
0
0
43
424
1.04
0.00
3.5
4.0
14.60
14.70
pmol/l
0.13
38
389
16
159
1.01
0.00
2.3
4.6
7.59
7.51
mmol/l
0.02
16
141
12
117
1.03
0.00
3.0
3.0
1.35
0.86
mg/l
0.35
12
88
34
339
1.01
0.00
4.3
3.5
—
—
—
0
0
14
142
0.98
0.00
1.6
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
286.20
—
0
5
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
159.48
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.8
—
20.33
—
0
6
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.0
—
—
—
0
0
6
65
0.92
-0.00
1.5
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
5.79
—
0
7
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.0
—
5.76
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
92.05
—
0
5
0
6
0.00
-0.00
0.0
2.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.3
—
18.04
—
0
8
0
5
0.00
-0.00
0.0
2.0
—
0.84
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint H7_VISUALPATHNAS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have H7_VISUALPATHNAS.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: H7_VISUALPATHNAS – Disorder of visual pathways, unspecified

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data